Chemokines and chemokine receptors play the key role in the regulation of targeted migration of leucocytes in the blood and tissues. They are involved in the pathogenesis of many diseases. Presently, special attention has been paid to the chemokine receptor CCR5. CCR5 is ascribed to the superfamily of transmembrane receptors conjugated with G-protein. The CCR5 protein is coded by CCR5 gene located on short arm of chromosome 3 at position 21 (3p21) [1] . There exists CCR5 delta32 polymorphism type representing deletion of 32 pairs of the nucleotides in the coding area of CCR5 gene. As a result of mutant gene expression in the homozygous state, shortened and functionally inactive CCR5 protein is translated [2, 3] . Homozygous carriers of CCR5 delta32 make nearly 1% of the representatives of the European race and heterozygous on average 10-15 %. Among representatives of the Negroid and Mongoloid races no homozygous carriers of CCR5 delta32 mutation have been found [4] .
Assessment of CCR5 delta32 polymorphism DNA was isolated from the cord blood samples frozen at -70°С using the PROTRANS kit (Protrans, Germany). Screening for CCR5 delta32 alleles was performed by means of the polymerase chain reaction (PCR) in the amplificator MyCycler, Ver. 1.065 (BioRad, USA). Polymorphism detection was done in 9%polyacrilamide gele using vertical electrophoresis. The length of PCR of fragments made 244 bp at wild type gene variant and 192 bp at homozygous CCR5 delta32 polymorphism.
HLA typing
HLA typing of umbilical cord blood specimens was performed by sequence-specific priming (SSP) method. DNA was isolated from 0.5-0.7 ml of umbilical cord blood using Protrans DNA Box 500 (Protrans, Germany). DNA concentration was estimated on spectrophotometer, mean value 70 μg/ml. Further we performed amplification by using Cyclerplate systems Protrans HLA-A*,-B*, -DRB1* (Protrans, Germany). Amplification was performed by using thermocycler MyCycler (BioRad, USA). Products of amplification placed in the gel wells and performed electrophoresis during 25 min at 170 V. In each of 96 wells there should appear control product for checking correct amplification. In some of the wells there should be the strip of specific product that defined the respective genotype by loci HLA-A, HLA-B and HLA-DRB1.
For detection of CCR5 delta32 polymorphism we examined 2860 umbilical cord blood samples from public registry of donors. As a result, 29 samples with CCR5 delta32/delta32 genotype were selected that made 1.0 %. In 493 samples (17.2 %) the CCR5 delta32 polymorphism was present in the heterozygous state (Table 1) .
Comparative analysis was carried out to see the distribution of HLA alleles among cord blood donors, selected at random, with the wild CCR5 genotype and among cord blood donors with CCR5 delta32/delta32 genotype (Table 2) .
High frequency of the most prevalent HLA alleles in the North-West of Russia was established among the donors of both groups (Table 3) .
Identification of the CCR5 delta32 polymorphism opened new possibilities for HIV-infection cure. Of today, transplantation of HSCs with CCR5 delta32/delta32 genotype has been the only method that allows eradicate HIV from the infected organism. However the use of bone marrow or peripheral blood samples from adult donors is practically inadmissible because of rare polymorphism occurrence in the population and observance of stringent compatibility conditions by HLA system in donor-recipient matching. At the same time cord blood HSCs could significantly more likely to be suitable for treating such patients.
The American investigators have defined that a Registry incorporating 300 units of mononuclear umbilical cord blood fraction with CCR5 delta32/ delta32 genotype will allow specimen selection for transplantation by HLA with 73.6%probability for children and 73.6%probability for adults and heterozygous state [8, 9] . Lowering of CCR5 protein expression on the membranes of malignant and stromal cells in the hematological patients with CCR5 delta32 mutation brings about their reduced response on anti-inflammatory chemokines that may be the positive factor limiting tumor spreading at lymphoproliferative diseases [10] .
In recent time CCR5 delta32 polymorphism has been studied actively in connection with its influence on the pathogenesis of Human Immunodeficiency Virus (HIV) infection. Earlier studies reported that the virus finds membrane CD4 receptor to be a suitable for its entry into cell [11, 12, 13] . However soon it became clear that for virus entry into cell it's binding with only one receptor is not sufficient. In 1996 five different research groups independently made a discovery that along with CD4 the HIV virus uses chemokine receptor CCR5 for penetration through cell membrane. Simultaneous expression of CD4 and CCR5 receptors occurs on T-lymphocytes, monocytes, macrophages and dendrite cells.
Presence of CCR5 delta32 in homozygous state determines synthesis of defective CCR5 receptor non-expressing itself on cell membrane. For this reason homozygous carriers of study polymorphism possess practically full resistance to HIV infecting [14, 15, 16, 17, 18] . One successful case of transplantation of peripheral blood hematopoietic stem cells (HSC) was performed in 2007 year in Germany to a HIV-infected patient with acute myeloid leucosis from the donor with CCR5 delta32/ delta32 genotype.
Following transplantation the highly active antiretroviral therapy was discontinued. Virus loading in blood plasma and bioptates of various organs including intestine, liver and lymph nodes remained at undetectable level till now [19, 20, 21] . However, despite a successful treatment this was the sole case and not a single HSC transplantation has been performed so far [22] . This circumstance is linked not only with rare incidence of CCR5 delta32 polymorphism but also with a need of stringent donor-recipient HLA matching. For successful bone marrow HSC and peripheral blood transplantation minimum 7 of 8 alleles must coincide in four HLA-А, -В, -С, -DRB1 loci during high-resolution typing [23, 24] . Such conditions create essential difficulties for selection of proper recipient in the inventory of donors of HSC and peripheral blood.
The hypothesis of the American research group headed by Prof. L. D. Petz states that HSC of umbilical cord blood with CCR5 delta32/ delta32 gene type could be used for transplantation to HIV-infected patients [25] . It is known that transplantation of umbilical cord blood HSC can be performed under less stringent conditions of histocompatibility: it is sufficient they are matched at 4 of 6 alleles in HLA-A and B loci at using low resolution typing and at HLA-DRB1 loci at using highresolution typing [26, 27] .
At present the cord blood is thought to be equivalent source of HSC along bone marrow and peripheral blood. First successful transplantation of umbilical cord blood was performed in 1988 in France to a 5-year patient with Fanconi anemia [28] . By the year 2011 more than 20,000 umbilical-cord blood HSC transplantations had been performed at the transplantation centers worldwide [29] . Numerous comparative investigations on bone marrow [30, 31] , peripheral blood [32, 33] and umbilical-cord blood HSC transplantations [34, 35, 36] demonstrate equivalent post-transplantation outcomes. Thus umbilical cord blood HSC transplantation could most probably find its clinical usage for cure of HIV-infected patients.
Hence the aim of this work was to evaluate the scientific-organizational possibilities for developing a public registry of umbilical cord blood with CCR5 delta32/delta32 genotype for cure of HIV-infected patients.
Total 2860 umbilical cord blood samples taken from an Registry of Pokrovsky bank of stem cells (St. Petersburg) were examined. These samples were screened for the presence of CCR5 delta32 polymorphism and distribution of HLA alleles. of the Europeoid race [25] . Moreover there are works demonstrating performance of successful transplantations of cord HSCs in combinations with haploidentical bone marrow transplantations [39, 40, 41] . In this case the probability of selection of appropriate cord blood donor for HSCs transplantation will reach 85.6%for children and 82.1%adult patients of the Europeoid race [25] . An additional proof of efficacious HSCs transplantation in HIV infection can be the clinical case where a double umbilical cord blood HSCs transplantation was performed in 34-year HIV-infected patient with acute myeloid leucosis. Retrospectively it was found that one of the cord blood donors was the homozygous carrier of CCR5 delta32 polimorphism. Investigation of chimerism showed complete engraftment of CCR5 delta32/delta32 cells. In vitro study carried out on day 123 following transplantation demonstrated that peripheral blood mononuclear cells of the patient were resistant to HIV-1 BAL (CCRtropic strain) and NL4-3 (CXCR4-tropic strain) [25] . Nowadays double or treble transplantation of HSCs is the worked-off technology allowing avoid limiting factor -insufficient cell number of umbilical cord blood that successfully extend the application of umbilical cord blood HSCs transplantation in adult recipients [42, 43] .
MATERIALS AND METHODS

RESULTS AND DISCUSSION
Cooperative work between numerous umbilical cord blood banks makes it highly probable to create a special storage of cord blood CCR5 delta32/delta32 specimens which, if need be, can be easily enlarged. It has been estimated that nearly 400,000 criopreserved cord blood specimens are stored worldwide among them 2,000-4,000 CCR5 delta32/delta32 samples [44] . Nevertheless, there is a need of creating regional inventory CCR5 delta32/delta32 of umbilical cord blood hematopoietic stem cells for increasing probability of finding compatible units for transplantation in view of the geographic variability of HLA alleles distribution. Indicative of this are the data about the prevalence of HLA alleles that have been received in this investigation. During a comparative analysis of the distribution of HLA alleles in cord blood donors with wild CCR5 genotype and cord blood donors with CCR5 delta32/delta32 genotype (Table 2) , we have disclosed the high occurrence of the most prevalent HLA alleles in the North-West Russia among the individuals of both groups (Table 3) .
Thus it would be most reasonable that search for respective specimen of HSCs for transplantation should be started in the region of recipient's origin. The suitable candidates for transplantation of cord HSCs with CCR5 delta 32/delta32 would be the HIV-infected individuals for whom transplantation of HSCs in connection with hematologic or other concomitant pathology is indicated. Also transplantation of cord blood HSCs with deletion alleles can be indicative for the HIV-infected patients who are resistant to antiretroviral therapy.
Our hypothesis, therefore, is that CCR5 delta32/delta32 cord blood units found during clinical investigations can be readily proposed for HIV infection cure in the Russian Federation and abroad. On the base of this work the National Cord Blood Inventory of umbilical cord blood with CCR5 delta32/delta32 genotype will be created in the North-West Federal region of the Russian Federation for HIV infection cure. 
